Advertisement

Topics

U.S. FDA to review Teva and Celltrion's cancer biosimilar drug

05:02 EDT 31 Jul 2017 | Reuters

JERUSALEM (Reuters) - Teva Pharmaceutical Industries and South Korea's Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.

Original Article: U.S. FDA to review Teva and Celltrion's cancer biosimilar drug

NEXT ARTICLE

More From BioPortfolio on "U.S. FDA to review Teva and Celltrion's cancer biosimilar drug"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...